Welcome to our dedicated page for Prenetics SEC filings (Ticker: PRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking a company that sells DNA tests, builds multi-cancer detection panels, and even secures data on the blockchain can feel overwhelming. Prenetics’ SEC filings blend consumer-nutrition details with highly technical genomic disclosures, making it hard to spot what truly moves the stock.
Stock Titan solves that problem. Our AI turns Prenetics’ 300-page annual report 10-K into a digestible brief, flags segment revenue from IM8 supplements versus Insighta diagnostics, and alerts you to Prenetics insider trading Form 4 transactions the instant they hit EDGAR. Need the latest numbers? The platform autogenerates plain-language highlights from every Prenetics quarterly earnings report 10-Q filing and attaches context so you understand R&D spend on new genomic assays.
Wondering which disclosures matter most? Browse a dedicated feed that maps each filing type to real questions investors ask:
- 10-K & 10-Q – revenue by division, regulatory milestones, liquidity trends
- 8-K material events explained – clinical-trial readouts or blockchain partnerships
- Form 4 insider transactions real-time – see if executives buy before data releases
- Proxy statement executive compensation – incentives tied to cancer-test approvals
Every document arrives with AI-powered summaries, keyword search, and cross-links—so understanding Prenetics SEC documents with AI becomes a five-minute task, not a weekend project. Whether you’re looking for a Prenetics earnings report filing analysis or need a Prenetics annual report 10-K simplified, Stock Titan keeps you ahead of the curve.
Prenetics Global Limited submitted a report describing a recent corporate update. On December 30, 2025, the company issued a press release announcing an update to its capital allocation strategy and the cessation of Bitcoin purchases. The report states that this press release is included as an exhibit and is being incorporated by reference into several existing Form F-3 and Form S-8 registration statements, allowing those registration documents to reflect the latest information about the company’s capital allocation approach.
Prenetics Global Limited reports that it will hold its 2025 annual general meeting of shareholders on December 19, 2025. The notice of annual general meeting is furnished as Exhibit 99.1 to this report.
The company also states that this report is incorporated by reference into its existing registration statements on Form F-3 (File Nos. 333-274762, 333-276538 and 333-288824) and Form S-8 (File Nos. 333-279019, 333-271552 and 333-267956), so the information becomes part of those registration statement disclosures.
Prenetics Global Limited reported that its Chief Executive Officer and co‑founder, Danny Sheng Wu Yeung, bought additional shares of the company in the open market. On November 19, 2025, he purchased 20,000 Class A Ordinary Shares at $13.00 per share, for a total purchase price of $260,000. Following this transaction, his total holdings of Class A Ordinary Shares increased to 96,412 shares. This reflects a personal capital commitment by the CEO using his own funds rather than an issuance of new shares by the company.
Prenetics Global Limited (PRE) reported that its Chief Executive Officer and co-founder, Danny Sheng Wu Yeung, bought additional company stock on the open market. On November 18, 2025, he purchased 20,118 Class A Ordinary Shares at a price of $12.02 per share, for a total of about $242,000. Following this transaction, his holdings in the company’s Class A Ordinary Shares increased to 76,412, signaling a higher personal stake in Prenetics’ future performance.
Prenetics Global Limited reported that its Chief Marketing Officer, Rahul Ramchand, bought 30,000 Class A ordinary shares on the open market on November 14, 2025. He paid $13.29 per share, for a total purchase price of $398,821. Following this transaction, his total holdings increased to 75,553 Class A ordinary shares of the company. This filing simply records the executive share purchase and resulting ownership level.
Prenetics Global Limited reported that its Chief Marketing Officer, Rahul Ramchand, purchased 30,000 Class A Ordinary Shares in the open market on November 12, 2025 at $13.17 per share, for a total of $395,151. Following this transaction, his holdings increased to 45,553 Class A Ordinary Shares.
The purchase was disclosed via a Form 6-K and reflects an executive open-market buy.
Prenetics Global Limited filed a Form 6‑K furnishing a press release with its unaudited financial results for the third quarter ended September 30, 2025. The filing states that this report is incorporated by reference into the company’s existing Form F‑3 and Form S‑8 registration statements. The press release is attached as Exhibit 99.1.
Prenetics Global Limited closed a best efforts public offering of 2,722,642 Class A ordinary shares, each sold together with one Class A warrant and one Class B warrant at a combined price of $16.08 per unit. The company reported gross proceeds of approximately $44 million.
The Class A and Class B warrants are immediately exercisable for up to 2,722,642 shares each at exercise prices of $24.12 and $32.16, respectively, and have a five-year term from closing. Dominari Securities LLC acted as sole placement agent; compensation was an 8% cash success fee (reduced to 4% for company-introduced investors). Prenetics also issued placement agent warrants to purchase 131,829 shares at $16.08.
Prenetics plans to use proceeds for global expansion of IM8, development and implementation of its Bitcoin treasury strategy, working capital, and general corporate purposes. The transaction was conducted under an effective Form F-3 and closed on October 28, 2025.
Prenetics Global Limited launched a primary offering of 2,722,642 Class A Ordinary Shares at $16.08 per share sold together with one Class A warrant and one Class B warrant, plus warrants to purchase up to 5,445,284 shares and Placement Agent Warrants to purchase up to 131,829 shares. Gross proceeds are $43,779,297.56 with estimated net proceeds of $40.1 million.
Each Class A warrant is exercisable at $24.12 and each Class B warrant at $32.16, both immediately exercisable and expiring five years from issuance; the warrants will not be listed and may have limited liquidity. Dominari Securities LLC acted as exclusive placement agent with fees of 8% (reduced to 4% for certain investors) and warrant coverage. Shares outstanding were 12,524,823 Class A and 1,580,972 Class B prior to the offering and will be 15,247,465 Class A and 1,580,972 Class B immediately after.
The Company intends to use proceeds to expand IM8 globally, develop and implement its Bitcoin treasury strategy, and for working capital and general corporate purposes. The filing highlights risks including immediate dilution, lack of a trading market for the warrants, PFIC considerations, and Bitcoin-related volatility and custody risks.
FAQ
What is the current stock price of Prenetics (PRE)?
What is the market cap of Prenetics (PRE)?
